Top

Published in:

01-06-2010 | Original Communication

Serum uric acid levels and neuromyelitis optica

Authors: Fuhua Peng, Xiufeng Zhong, Xuhui Deng, Wei Qiu, Aimin Wu, Youming Long, Xueqiang Hu, Qing Li, Ying Jiang, Yongqiang Dai

Published in: Journal of Neurology | Issue 6/2010

Abstract

Uric acid (UA) has been reported to be reduced in the serum of patients with multiple sclerosis (MS) and optic neuritis (ON). However, the relationship between UA and neuromyelitis optica (NMO) was unknown. NMO was claimed to be a distinct nosologic entity from MS. The aim of our study was to investigate the correlation between serum UA level and the clinical characteristics of NMO. The serum UA level was measured in 403 Chinese patients; 69 with NMO, 32 ON, 127 MS, 80 cerebral infarction (CI) patients, and 95 healthy controls (CTL). Serum UA level in NMO was significantly lower than that in CI (249.89 ± 93.74 vs. 315.42 ± 85.57 μmol/L, p = 0.004) and CTL (249.89 ± 93.74 vs. 314.33 ± 102.05 μmol/L, p < 0.0001). However, no difference was found between NMO and MS (p = 0.496) or NMO and ON (p = 0.858). When the analysis was performed in the female cohort separately, UA level was significantly lower in females than in males in all groups. It was also shown in our study that UA level in patients with NMO was not correlated with disease activity revealed by MRI, disease disability or duration of disease. Our results indicated a reduced serum UA level in patients with NMO.

Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, Koprowski H (1997) Prevention of experimental allergic encephalo-myelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94:2528–2533CrossRefPubMed

Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:6858–6862CrossRefPubMed

Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, Spitsin SV (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14:691–698PubMed

Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalo-myelitis and multiple sclerosis. Proc Natl Acad Sci USA 95:675–680CrossRefPubMed

Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99:16303–16308CrossRefPubMed

Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–2214PubMed

Argyriou AA, Makris N (2008) Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 118(4):209–217CrossRefPubMed

Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood–brain barrier dysfunction. Eur J Neurol 9:221–226CrossRefPubMed

Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D (2006) Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108:527–531CrossRefPubMed

10.

Knapp CM, Constantinescu CS, Tan JH, McLean R, Cherryman GR, Gottlob I (2004) Serum uric acid levels in optic neuritis. Mult Scler 10:278–280CrossRefPubMed

11.

Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X, Qiu W, Pei Z (2008) Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14(2):188–196CrossRefPubMed

12.

Miller A, Glass-Marmor L, Abraham M, Grossman I, Shapiro S, Galboiz Y (2004) Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin Neurol Neurosurg 106:249–254CrossRefPubMed

13.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMed

14.

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489CrossRefPubMed

15.

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMed

16.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846CrossRefPubMed

17.

Lucchinetti CF, Parisi J, Bruck W (2005) The pathology of multiple sclerosis. Neurol Clin 23(1):77–105CrossRefPubMed

18.

Calabrese V, Lodi R, Tonon C (2005) Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich’s ataxia. J Neurol Sci 233:145–162CrossRefPubMed

19.

Pentón-Rol G, Cervantes-Llanos M, Martínez-Sánchez G, Cabrera-Gómez JA, Valenzuela-Silva CM, Ramírez-Nuñez O, Casanova-Orta M, Robinson-Agramonte MA, Lopategui-Cabezas I, López-Saura PA (2009) TNF-alpha and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica. J Inflamm (Lond) 6:18CrossRef

20.

Kanwar JR (2005) Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr Med Chem 12:2947–2962CrossRefPubMed

21.

Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC (2005) Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 102:3483–3488CrossRefPubMed

22.

Kastenbauer S, Koedel U, Pfister HW (1999) Role of peroxynitrite as a mediator of pathophysiological alterations in experimental pneumococcal meningitis. J Infect Dis 180:1164–1170CrossRefPubMed

23.

Drulović J, Dujmović I, Stojsavljević N, Mesaros S, Andjelković S, Miljković D, Perić V, Dragutinović G, Marinković J, Lević Z, Mostarica Stojković M (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126CrossRefPubMed

24.

Koprowski H, Spitsin SV, Hooper DC (2001) Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 49:139CrossRefPubMed

25.

Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992: National Health and Nutrition Examination Survey. JAMA 283:2404–2410CrossRefPubMed

26.

Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, Rosati G (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23:183–188CrossRefPubMed

27.

Wingerchuk DM, Weinshenker BG (2005) Neuromyelitis Optica. Curr Treat Options Neurol 7:173–182CrossRefPubMed

Title: Serum uric acid levels and neuromyelitis optica
Authors: Fuhua Peng
Xiufeng Zhong
Xuhui Deng
Wei Qiu
Aimin Wu
Youming Long
Xueqiang Hu
Qing Li
Ying Jiang
Yongqiang Dai
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 6/2010
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-010-5455-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum uric acid levels and neuromyelitis optica

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Having the vision to measure calcium

T1ρ and T2ρ MRI in the evaluation of Parkinson’s disease

JCV detection in multiple sclerosis patients treated with natalizumab

High frequency of exon 10 mutations in the NOTCH3 gene in Italian CADASIL families: phenotypic peculiarities

Analysis of long-standing nociceptive and neuropathic pain in patients with post-polio syndrome

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy